Drug Use Survey (DUS) of Triple Therapy (Methycobal (MBL)+ Myonal (MYO)+ Non-steroidal Anti-inflammatory Drags (NSAID)) on the Symptom Relief of Lumbar DDD in China

Eisai

Status: Completed

Conditions: Lumbar Disc Degenerative Disease

Study type: Observational

Funder types: Industry

Identifiers

NCT01299077

EISAI-MBL-2010-1

Details and patient eligibility

About

The purpose of this study is to observe the overall satisfaction of patients with degenerative disc disease after receiving triple therapy.

Full description

DDD (lumbar disc degenerative disease ) patients who have been prescribed triple therapy (MBL+ MYO+ NSAIDs) over 2 weeks of triple therapy were enrolled in the study. They were asked to assess their overall satisfaction degree on triple therapy.

Enrollment: 478 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. lumbar degenerative disc disease (DDD)
2. patients who have been prescribed over 2 weeks of triple therapy

Exclusion criteria

Patients who do not meet inclusion criteria for DDD

Trial design

478 participants in 1 patient group

Lumbar disc degenerative disease

Description:

Triple therapy (MBL+ MYO+ NSAIDs) which prescribed by doctors (Drs) based on disease condition